価格表

在庫・価格 : 2025年09月12日 08時09分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-SALL4, Mouse-Mono(6E3)
データシート※最新のデータシートでない場合があります
H00057167-M03 ABNアブノヴァ
Abnova Corporation
100 μg ¥77,000
(発注済)
追加

在庫・価格 : 2025年09月12日 08時09分 現在

Anti-SALL4, Mouse-Mono(6E3)

  • 商品コード:H00057167-M03
  • メーカー:ABN
  • 包装:100μg
  • 価格: ¥77,000
  • 在庫:無(発注済)
使用文献
No. 文献情報 備考 参照
1 Shibahara J et al., Clinicopathologic characteristics of SALL4-immunopositive hepatocellular carcinoma., SpringerPlus 2014, 3:721 doi:10.1186/2193-1801-3-721

PubMed
2 Kohashi K et al., ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors: a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor., Human Pathology(2014), doi: 10.1016/j.humpath. 2014.10.010

PubMed
3 Yonemaru J et al. A yolk sac tumor of the pancreas and derived xenograft model effectively responded to VIP chemotherapy. Pancreatology 2020 Apr;20(3):551-557
Yonemaru J et al
2020/01/01
PubMed
4 Kobayashi T et al. Neonatal streptozotocin treatment rapidly causes different subtype of hepatocellular carcinoma without persistent hyperglycemia in 4CS mice fed on a normal diet. Pathol Res Pract 2021 Sep;225:153559
Kobayashi T et al
2021/01/01
PubMed
5 Kawachi H et al. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma. Immunotherapy 2021 07;13(10):799-806
Kawachi H et al
2021/01/01
PubMed
6 Kishikawa S et al. Distinct properties of pure- and mixed-type high-grade fetal lung adenocarcinomas by genetic profiling and transcription factor expression. Virchows Arch 2022 Mar;480(3):609-619
Kishikawa S et al
2022/01/01
PubMed
7 Shibahara J et al. Clinicopathologic characteristics of SALL4-immunopositive hepatocellular carcinoma. Springerplus 2014;3:721
Shibahara J et al
2014/01/01
PubMed
8 Kohashi K et al. ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors: a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum. Pathol. 2015 Feb;46(2):225-30
Kohashi K et al
2015/01/01
PubMed
9 Akiyama T et al. Establishment and characterization of NCC-MRT1-C1: a novel cell line of malignant rhabdoid tumor. Hum Cell 2022 Nov;35(6):2002-2010
Akiyama T et al
2022/01/01
PubMed
10 Ota T et al. The first case of SMARCA4-deficient sarcoma of stomach. Clin J Gastroenterol 2022 Jun;15(3):531-536
Ota T et al
2022/01/01
PubMed
11 Chapman KM et al. Rattus norvegicus Spermatogenesis Colony-Forming Assays. Methods Mol Biol 2023;2677:233-257
Chapman KM et al
2023/01/01
PubMed
  • No.: 1
  • 文献情報:
    Shibahara J et al., Clinicopathologic characteristics of SALL4-immunopositive hepatocellular carcinoma., SpringerPlus 2014, 3:721 doi:10.1186/2193-1801-3-721

  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Kohashi K et al., ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors: a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor., Human Pathology(2014), doi: 10.1016/j.humpath. 2014.10.010

  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Yonemaru J et al. A yolk sac tumor of the pancreas and derived xenograft model effectively responded to VIP chemotherapy. Pancreatology 2020 Apr;20(3):551-557
    Yonemaru J et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Kobayashi T et al. Neonatal streptozotocin treatment rapidly causes different subtype of hepatocellular carcinoma without persistent hyperglycemia in 4CS mice fed on a normal diet. Pathol Res Pract 2021 Sep;225:153559
    Kobayashi T et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Kawachi H et al. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma. Immunotherapy 2021 07;13(10):799-806
    Kawachi H et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Kishikawa S et al. Distinct properties of pure- and mixed-type high-grade fetal lung adenocarcinomas by genetic profiling and transcription factor expression. Virchows Arch 2022 Mar;480(3):609-619
    Kishikawa S et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Shibahara J et al. Clinicopathologic characteristics of SALL4-immunopositive hepatocellular carcinoma. Springerplus 2014;3:721
    Shibahara J et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Kohashi K et al. ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors: a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum. Pathol. 2015 Feb;46(2):225-30
    Kohashi K et al
    2015/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Akiyama T et al. Establishment and characterization of NCC-MRT1-C1: a novel cell line of malignant rhabdoid tumor. Hum Cell 2022 Nov;35(6):2002-2010
    Akiyama T et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Ota T et al. The first case of SMARCA4-deficient sarcoma of stomach. Clin J Gastroenterol 2022 Jun;15(3):531-536
    Ota T et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Chapman KM et al. Rattus norvegicus Spermatogenesis Colony-Forming Assays. Methods Mol Biol 2023;2677:233-257
    Chapman KM et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed